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Soon after introducing recombinant hepatitis B virus 
(HBV)  vaccine,  universal  neonatal  vaccination  became 
the corner stone of the preventive measures for this po-
tentially life threatening infection (1-3). By 2006 more 
than 177 out of 193 member states of world health orga-
nization  (WHO)  introduced  HBV  vaccination  in  their 
national infant immunization programs (1). Following a 
complete series of vaccination during neonatal period, 
protective antibody level raises in more than 95% of in-
fant’s blood test up to 18 months after vaccination (3-5). 
The effectiveness of this strategy has been shown by sev-
eral investigators in reducing the incidence of HBV car-
rier rate and probably cirrhosis and hepatocellular car-
cinoma (1, 2, 5-7).
A level of 10 IU/L of anti hepatitis B surface antibody 
(Anti HBsAb) is usually considered as a protective level 
against  future  infections.  Although  this  level  was  ini-
tially determined in studies about passive prophylaxis 
of HBV infection, the same level was arbitrary applied to 
active immunization though this was debated by some 
researchers (8-10).  Universally there is a consistent de-
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cline in antibody titer over time .The reported rate of per-
sistent protective level of Anti HBsAb titers varied from 
33% up to 79%, at least 5 year after vaccination (10-14). 
Currently about 21% of worldwide HBV related mortali-
ties are linked to the vertical transmission, and the other 
depends on unsafe injection and high risk behavior that 
causes more concern of long lasting immunity extend-
ing to adolescent and even adulthood (1, 2, 5).
Tosun  et  al.  (15)  in  a  published  article  in  Hepatitis 
Monthly reported that the protective level of antibod-
ies 9 years after neonatal vaccination was roughly near 
50% in children from Turkey (15). Although the authors 
of the mentioned study have checked the health records 
and enrolled only those received complete vaccination, 
there were still many infants who did not receive vacci-
nation appropriately. So, there was a wide variation of 
utilization of HBV vaccination both within and between 
countries.
The coverage of complete vaccination of infants against 
HBV was estimated 69% in 2008 worldwide (1, 5) while 
this  rate  for  neonatal  received  vaccination  within  24 
hours after birth was about 27% globally with a wide vari-
ation among countries (3-71%) (1, 5). Later immunization 
may leave the neonates vulnerable to possible transmis-
sions both horizontally (e.g. within the health services or 
through household contacts with infected family mem-
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 Implication for health policy/practice/research/medical edu-
cation:
Since HBV prevention and need assessment for its vaccination 
has high priority in each population, we decide to draw read-
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bers) and vertically (2, 8, 9) that leads to WHO recommen-
dation regarding implementation of neonatal vaccina-
tion against HBV within the first 24 hours of life (5, 9).
Some  problems  such  as  maintaining  cold  chain  in 
transportation  and  handling  of  vaccine,  improper  in-
jection and other technical problems in this context are 
still real challenges in many countries making effective-
ness of vaccination, like HBV which need a stable cold 
chain, lower than expected in real practice (2, 5, 8, 9). For 
instance a recent study from Mongolia mentioned that 
the HBV incidence rate after 7-12 years of vaccination was 
more than two times in rural infants who received HBV 
vaccination  in  winter  compared  to  other  seasons  (16) 
which probably is related to vulnerable cold chain. Some 
studies showed that those who were born of infected 
mothers specially mothers with higher HBV DNA level 
have lower rate of vaccination response (17, 18). According 
to available studies on HBV screening during pregnancy 
in Turkey, 2.1-12.3% of Turkish women infected with HBV in 
different geographic locations (19-21). The status would 
be probably much higher if Anti HBc Ab was measured. 
In Tosun’s study only two children were HBsAg positive 
(0.15%). There would be a concern whether a proportion 
of non-responders have been born to HBV infected moth-
ers and were infected vertically. There is also possibility 
of being infected horizontally in early childhood. 
The  HBV  infection  rate  in  children  received  vaccina-
tion after determining by Anti HBcAb positivity might be 
as high as 0.5% (11). The impacts of childhood infection 
probably would not be high in the population studied 
by Tosun although in her study Anti HBcAb status of chil-
dren were not evaluated.
Tosun et al. also reported lower protection rate in lower 
socioeconomic  groups  compared  to  middle  and  high 
classes and in those who were delivered in health insti-
tution versus those who were delivered elsewhere. There 
are many reports on high prevalence of HBV carriers (1, 
2, 5, 9) and few HBV vaccination (9, 22, 23) among lower 
socioeconomic groups. But we are not informed of any 
previous reports showing the lower response rate to HBV 
vaccine in lower socioeconomic classes. There could be 
many confounding factors including malnutrition, con-
comitant diseases or even receiving vaccine in bad tech-
niques such as inappropriate handling of vaccine includ-
ing stable and sustained the cold chain (8, 9, 16, 24, 25). 
This issue needs to be confirmed in larger studies and 
needs to be analyzed in more details to find the possible 
etiology of such difference.
After all we still confront with this major question: How 
long the protective effect of neonatal HBV vaccination 
persists? Is there a need for booster after complete series 
of vaccination? If so when this booster should be admin-
istered and to whom? Should it be universal like the neo-
natal vaccination itself or only be given after monitoring 
or given only to selected groups? 
Answer  to  these  questions  is  not  easy  and  there  are 
contradictory evidences in the literature. The debate is 
whether the reduction in antibody levels is indicating 
lower  immunity  or  not.  An  anamnestic  response  may 
occur  when  people  who  were  previously  immunized 
against an antigen are re-exposed to the same antigen (9, 
10, 26). How can we be sure that the same would not be 
happened to the children when they re-exposed to the 
virus? The persistence of specific B cell population com-
mitted to antibody production against HBsAg has been 
shown  years  after  vaccination  (26).  In  a  recent  report 
from Taiwan, researchers have shown that after   20 years 
post vaccination the immune system memory is lost in 
up to 80% of vaccines (27). As with all experimental stud-
ies it would be debatable to apply this laboratory based 
study to real practice specially considering other contra-
dictory studies (9-12, 28, 29). A recent Cochrane review 
was not able to identify any randomized study to assess 
the benefit of booster vaccination in prevention of HBV 
(30). 
The  same  group  reported  the  rate  of  breakthrough 
infection among vaccines was less than 0.1% (31). Even 
chronic infection may not develop in those patients if 
they have completed their HBV vaccine series. They also 
concluded the protection provided by complete series of 
monovalent HB vaccine persists for at least two decades 
in  the  vast  majority  of  general  population  and  they 
found that there was no evidence of need for booster vac-
cination, although they recommended further studies to 
assess the need for booster in different subgroups (31). 
In conclusion we still do not have enough evidence to 
recommend universal booster vaccination. None of the 
international guidelines for HBV vaccination currently 
recommend booster dose (1-3, 5, 8, 9). Probably in some 
high risk groups this might be of real concern though ev-
idence for this recommendation does not exist. We need 
more detailed long term studies to change our current 
recommendation of no need for booster vaccination.
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